In breast cancer, 16α-[18F]fluoro-17β-estradiol (FES)–PET has demonstrated higher radiotracer uptake and greater lesion detection rates compared to FDG–PET in estrogen receptor (ER)–positive breast cancer [52]. Here, ESR1 is linked to breast carcinoma.